Thus, it is crucial to measure serum IL-6 concentrations rapidly and repeatedly during treatment courses to facilitate the timely identification of either CAP or COVID-19 patients at risk of developing acute respiratory failure. This evidence concerns the gene IL6 and acute respiratory failure.